elio tissue complete

A pan solid tumor CGP test

elio TISSUE COMPLETE

Actionable insights.
Personalized care.

The PGDx elio™ tissue complete test enables rapid and actionable genomic insights for all patients with advanced cancer. Our FDA cleared comprehensive tumor profiling kit is available for labs to help every patient receive the personalized treatment options they deserve.

Fast

Automated results generated in 4 – 5 days (vs. as many as 30 days for send out)

Actionable

500+ solid tumor-related genes, with easy-to-interpret reports clearly highlighting genetic alterations that could impact care decisions

Trustworthy

FDA cleared and CE-IVD marked with overall clinical pass rate of 92.9%

Accessible

Retain complete control over specimens and data, while unlocking new potential paths to reimbursement

elio TISSUE COMPLETE

Product overview

Benefits of the PGDx pan solid tumor CGP test

Equip your lab to deliver better insights

PGDx elio tissue complete enables you to confidently advise your oncologists and gain new research advantages with our sample-to-answer IVD kit that includes fully automated bioinformatics and dedicated customer support.

Backed by robust bioinformatics

PGDx elio bioinformatics rapidly and accurately identifies cancer mutations, empowering every lab to provide timely and trustworthy results. High quality training data, expert curation and machine learning algorithms combine to provide best-in-class identification of cancer mutations.

Enable personalized treatment decisions

PGDx elio tissue complete makes precision oncology available in-house so you can quickly access comprehensive tumor insights. That empowers you to make timely treatment decisions that optimize outcomes.

Backed by robust bioinformatics

PGDx elio bioinformatics rapidly and accurately identifies cancer mutations, empowering every lab to provide timely and trustworthy results. High quality training data, expert curation and machine learning algorithms combine to provide best-in-class identification of cancer mutations.

Accelerate your path to commercialization

PGDx elio tissue complete is the only FDA cleared comprehensive genomic profiling kit on the market, eliminating the need for time-consuming and costly validation. Standardized, distributed kits enable global access to patient cohorts relevant for your clinical trials.

Backed by robust bioinformatics

PGDx elio bioinformatics rapidly and accurately identifies cancer mutations, empowering every lab to provide timely and trustworthy results. High quality training data, expert curation and machine learning algorithms combine to provide best-in-class identification of cancer mutations.

CLINICAL TRIALS

See how elio solutions can inform research

Researchers all around the world are using elio tissue complete. Here are some of the breakthroughs that have been made possible.

FIDES trials with Basilea

Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02).

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03).

Learn More
KEYNOTE-495 with Merck

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475 – 495/KEYNOTE-495).

Learn More
MRD trial with NKI

Prevention of recurrent disease by additional chemotherapy in patients with detectable circulating tumor DNA in the blood after surgery for stage II (lymph nodes unaffected) colon cancer.

Learn More
TECHNICAL INFORMATION
elio tissue complete product specs

This test identifies somatic mutations with high accuracy and sensitivity, providing information on single nucleotide variants (SNVs), insertions/​deletions (indels), amplifications, translocations, microsatellite instability (MSI) status and tumor mutation burden (TMB) for use by qualified professionals to guide treatment decisions.

Resources

CUSTOMER PORTAL
Review technical documents & sample reports
SUPPORT
Get help now

Start using elio tissue complete